Strides Pharma Science Ltd - 532531 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) Strides Pharma Science Ltd - 532531 - Intimation Pursuant To Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)
We would like to inform that the Board of Directors of the Company in their meeting held on November 10, 2021, have considered and approved the request received from few Promoters/ Promoter Group of the Company seeking reclassification of their shareholding from 'Promoters/ Promoter Group' to 'Public' category. As required under SEBI Listing Regulations, we also enclose herewith extract of Minutes of Meeting of the Board of Directors held on November 10, 2021 approving such re-classification, for your reference. The Company will seek Members' approval for the reclassification in line with the provisions of Regulation 31A of SEBI Listing Regulations in due course. Request you to kindly take the same on record and oblige. Q2FY22 Quarterly Result Announced for Strides Pharma Science Ltd.
Highlights: Q2FY22 Consolidated revenues at Rs. 7,360 m An EBITDA breakeven of Rs. 10 m Successfully completes acquisition of Chestnut Ridge site along with ANDA’s from Endo Commenting on the performance, Dr R Ananthanarayanan, Managing Director & CEO, remarked, “We have reported an operational breakeven in Q2FY22 enabled by a bounce back in other regulated markets, growing 27% QoQ. The performance in other regulated markets was driven by improving demand scenario and resumption of our supplies to partners during the quarter post the Covid related manufacturing disruptions in Q1. Emerging markets continues to track well delivering growth both in Africa and Institutional business. We continue to face headwinds in our US business. While we have been able to retain volume share on our key products, we continued to witness price challenges in our portfolio during the quarter, magnified by concentration towards acute products. We have completed the strategic acquisition of Chestnut Ridge site in the US along with a portfolio of approved products which will enable us to accelerate new product launches. While there are near term headwinds, we remain optimistic on the US business in the long run. We will start witnessing improvement in our US business starting Q3FY22 and will continue the growth momentum there on. Given the volatile dynamics we believe we will only be able to achieve our current year guided outlook for US in FY23 A muted sales performance accompanied with a drop in gross margins and relatively higher operating costs has led to a negative operating leverage in H1. While cost measures have been initiated to improve operating leverage, the shift will be visible in the coming quarters.” Result PDF Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30, 2021
We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and half year ended September 30, 2021, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 11:00 hrs and concluded at 13:30 hrs. This is for your information and record. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for discussion of un-audited financial results for the quarter and half-year ended September 30, 2021 Strides will get bigger on the home run
Backed by economic revival, record low interest rates and stable prices, India's residential real estate market is set to see growing demand Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2021 ,inter alia, to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Wednesday, November 10, 2021 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2021, amongst other matters. Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed from Friday, October 1, 2021 upto Friday, November 12, 2021 (both days inclusive). This is for your kind information and record purposes. Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 03, 2021 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of shares under Strides ESOP 2016 Plan Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015